Skip to content
MARKETS / NYSE / WRBY
NYSE · OPHTHALMIC GOODS · LARGE CAP

Warby Parker Inc. WRBY

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$871.9M
▲ 13.0% YoY
$1.6M
$43.7M
▲ 26.0% YoY
In brief

What this company does

Warby Parker designs its eyewear in-house at its New York City headquarters and sells it directly to customers, with pricing starting at $95 including prescription lenses. It has expanded beyond glasses to offer eye exams, contact lenses, lens enhancements, and tech-enabled tools including Virtual Try-On and Virtual Vision Test. Its contact lens assortment includes brands such as Acuvue, Biofinity, DAILIES, and Precision1. In most of its stores, it provides in-person eye exams using digital retinal imaging, with optometrists employed directly by the company or by independent professional corporations or similar entities under contractual agreements. It operates in-house optical laboratories in Sloatsburg, New York, and Las Vegas, Nevada. The company operates across digital commerce and 323 retail stores as of December 31, 2025. As of December 31, 2025, it had 4,036 employees, including 2,275 full-time and 1,761 part-time employees, across two in-house optical laboratories and two offices in the United States. In June 2021, it elected to be treated as a public benefit corporation under Delaware law.

Written from the business description in Warby Parker Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth
USD 871.9M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 871.9 · Net income 1.6
400M800M-50M-100M2019202020212022202320242025
Compound annual growth
+13.4%
+17.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +17.2% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
0 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating -0.6% · Net 0.2%
-10%-20%2019202020212022202320242025
ROE
FY2025 · ROE 0.5%
-100%-200%-300%2019202020212022202320242025

Each USD of equity produced 0 cents of profit this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 43.7
20M40M-40M-80M2019202020212022202320242025
Net buybacks $M Dividends $M
FY2023 · Dividends — · Net buybacks 0.0
40M20192020202120222023

Total assetsUSD 720.9M
EquityUSD 367.7M
CashUSD 286.4M
Current ratio2.35×

Equity funds 51% of total assets.

The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019
Revenue $B0.90.80.70.60.50.40.4
Operating income $B−0.0−0.0−0.1−0.1−0.1−0.1−0.0
EBITDA $B0.00.0−0.0−0.1−0.1−0.00.0
Income tax $B0.00.00.00.00.00.00.0
Net income $B0.0−0.0−0.1−0.1−0.1−0.10.0
Free cash flow $B0.00.00.0−0.0−0.10.0−0.0
EPS, diluted $0.01−0.17−0.54−0.96−2.21−1.05−1.10
Dividend / sh $·······
Payout %·······
ROE %0.5−6.4−21.5−38.6−328.3··

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 33 reconciliationsAUDITED

Reconciled in 7 of 19 fiscal years. 62 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityOphthalmic Goods
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2019

Share this section

Download image